Long-term management of thrombocytosis in essential thrombocythaemia

Annals of Hematology

Volumn 88, Issue 1, 2009, Pages 1-10

  Birgegård, Gunnar ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Anagrelide; Essential thrombocythaemia; Hydroxycarbamide; Interferon; Myeloproliferative disorder

Indexed keywords

ACETYLSALICYLIC ACID; ALKYLATING AGENT; ALPHA INTERFERON; ANAGRELIDE; BUSULFAN; HYDROXYUREA; JANUS KINASE 2; PEGINTERFERON ALPHA; PHOSPHORUS;

ACUTE GRANULOCYTIC LEUKEMIA; ALOPECIA; ANEMIA; ANTICOAGULATION; ARTHRITIS; AUTOIMMUNE DISEASE; AUTOIMMUNE THYROIDITIS; BASAL CELL CARCINOMA; BLEEDING; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; ERYTHROCYTE COUNT; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; GENE MUTATION; GENETIC RISK; GRANULOCYTOPENIA; HIGH RISK PATIENT; HUMAN; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; ISCHEMIC OPTIC NEUROPATHY; LEG ULCER; LEUKOPENIA; LONG TERM CARE; LOW DRUG DOSE; MANIA; MOOD DISORDER; MYALGIA; MYELOFIBROSIS; NAIL COLOR DEFECT; NAUSEA; PATIENT CARE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK MANAGEMENT; RISK REDUCTION; SIDE EFFECT; SKIN ATROPHY; SKIN TUMOR; SKIN ULCER; SQUAMOUS CELL CARCINOMA; TACHYCARDIA; THROMBOCYTHEMIA; THROMBOCYTOSIS; THROMBOSIS; UNSPECIFIED SIDE EFFECT; XEROSIS;

ALGORITHMS; ANTINEOPLASTIC AGENTS; ASPIRIN; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; HYDROXYUREA; INTERFERON-ALPHA; JANUS KINASE 2; PREGNANCY; PUBMED; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THROMBOCYTHEMIA, ESSENTIAL; THROMBOCYTOSIS;

EID: 57049110356     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-008-0531-7     Document Type: Review

References (112)

1. Briere JB (2007) Essential thrombocythemia. Orphanet J Rare Dis 2:3 doi: 10.1186/1750-1172-2-3
2. Jensen MK, de Nully Brown P, Nielsen OJ, Hasselbalch HC (2000) Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area. Eur J Haematol 65:132-139 doi: 10.1034/j.1600-0609.2000.90236.x
3. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT et al (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: A prospective study. Lancet 366:1945-1953 doi: 10.1016/S0140-6736(05)67785-9
4. Sanchez S, Ewton A (2006) Essential thrombocythemia: A review of diagnostic and pathologic features. Arch Pathol Lab Med 130:1144-1150
5. Penninga EI, Bjerrum OW (2006) Polycythaemia vera and essential thrombocythaemia: Current treatment strategies. Drugs 66:2173-2187 doi: 10.2165/00003495-200666170-00003
6. Harrison CN, Gale RE, Machin SJ, Linch DC (1999) A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood 93:417-424
7. Griesshammer M, Klippel S, Strunck E, Temerinac S, Mohr U, Heimpel H et al (2004) PRV-1 mRNA expression discriminates two types of essential thrombocythemia. Ann Hematol 83:364-370 doi: 10.1007/s00277-004-0864-9
8. Teofili L, Pierconti F, Di Febo A, Maggiano N, Vianelli N, Ascani S et al (2002) The expression pattern of c-mpl in megakaryocytes correlates with thrombotic risk in essential thrombocythemia. Blood 100:714-717 doi: 10.1182/blood.V100.2.714
9. Kralovics R, Buser AS, Teo SS, Coers J, Tichelli A, van der Maas AP et al (2003) Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood 102:1869-1871 doi: 10.1182/ blood-2003-03-0744
10. Carobbio A, Finazzi G, Guerini V, Spinelli O, Delaini F, Marchioli R et al (2007) Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: Interaction with treatment, standard risk factors, and JAK2 mutation status. Blood 109:2310-2313 doi: 10.1182/ blood-2006-09-046342
11. Harrison CN (2005) Essential thrombocythaemia: Challenges and evidence-based management. Br J Haematol 130:153-165 doi: 10.1111/ j.1365-2141.2005.05543.x
12. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA et al (2007) Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: Recommendations from an ad hoc international expert panel. Blood 110:1092-1097 doi: 10.1182/ blood-2007-04-083501
13. Thiele J, Kvasnicka HM (2007) Myelofibrosis - what's in a name? Consensus on definition and EUMNET grading. Pathobiology 74:89-96 doi: 10.1159/000101708
14. Kvasnicka HM, Thiele J (2006) The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera. Semin Thromb Hemost 32:362-371 doi: 10.1055/s-2006-942757
15. Thiele J, Kvasnicka HM, Schmitt-Graeff A, Zankovich R, Diehl V (2002) Follow-up examinations including sequential bone marrow biopsies in essential thrombocythemia (ET): A retrospective clinicopathological study of 120 patients. Am J Hematol 70:283-291 doi: 10.1002/ajh.10116
16. Buhr T, Georgii A, Choritz H (1993) Myelofibrosis in chronic myeloproliferative disorders. Incidence among subtypes according to the Hannover Classification. Pathol Res Pract 189:121-132
17. Kreft A, Buche G, Ghalibafian M, Buhr T, Fischer T, Kirkpatrick CJ (2005) The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: A retrospective evaluation of sequential bone marrow biopsies. Acta Haematol 113:137-143 doi: 10.1159/000083452
18. Wilkins BS, Erber WN, Bareford D, Buck G, Wheatley K, East CL et al (2008) Bone marrow pathology in essential thrombocythemia: Interobserver reliability and utility for identifying disease subtypes. Blood 111:60-70 doi: 10.1182/blood-2007-05-091850
19. Colwell JA (2006) Aspirin for the primary prevention of cardiovascular events. Timely Top Med Cardiovasc Dis 10:E25
20. Landolfi R, Ciabattoni G, Patrignani P, Castellana MA, Pogliani E, Bizzi B et al (1992) Increased thromboxane biosynthesis in patients with polycythemia vera: Evidence for aspirin-suppressible platelet activation in vivo. Blood 80:1965-1971
21. Rocca B, Ciabattoni G, Tartaglione R, Cortelazzo S, Barbui T, Patrono C et al (1995) Increased thromboxane biosynthesis in essential thrombocythemia. Thromb Haemost 74:1225-1230
22. Randi ML, Rossi C, Fabris F, Menapace L, Girolami A (1999) Aspirin seems as effective as myelosuppressive agents in the prevention of rethrombosis in essential thrombocythemia. Clin Appl Thromb Hemost 5:131-135 doi: 10.1177/107602969900500210
23. van Genderen PJ, Mulder PG, Waleboer M, van de Moesdijk D, Michiels JJ (1997) Prevention and treatment of thrombotic complications in essential thrombocythaemia: Efficacy and safety of aspirin. Br J Haematol 97:179-184 doi: 10.1046/j.1365-2141.1997.d01-2127.x
24. Michiels JJ, Koudstaal PJ, Mulder AH, van Vliet HH (1993) Transient neurologic and ocular manifestations in primary thrombocythemia. Neurology 43:1107-1110
25. van Genderen PJ, Michiels JJ, van Strik R, Lindemans J, van Vliet HH (1995) Platelet consumption in thrombocythemia complicated by erythromelalgia: Reversal by aspirin. Thromb Haemost 73:210-214
26. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C et al (2004) Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 350:114-124 doi: 10.1056/NEJMoa035572
27. Griesshammer M, Bangerter M, van Vliet HH, Michiels JJ (1997) Aspirin in essential thrombocythemia: Status quo and quo vadis. Semin Thromb Hemost 23:371-377
28. Navarra P, Preziosi P (1999) Hydroxyurea: New insights on an old drug. Crit Rev Oncol Hematol 29:249-255 doi: 10.1016/S1040-8428(98)00032-8
29. Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F et al (1995) Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 332:1132-1136 doi: 10.1056/ NEJM199504273321704
30. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D et al (2005) Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353:33-45 doi: 10.1056/NEJMoa043800
31. Lofvenberg E, Wahlin A (1988) Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. Eur J Haematol 41:375-381
32. Randi ML, Ruzzon E, Luzzatto G, Tezza F, Girolami A, Fabris F (2005) Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders. Haematologica 90:261-262
33. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T (2003) Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis. Blood 101:3749 doi: 10.1182/blood-2003-01-0135
34. Gisslinger H, Kralovics R, Gotic M, Holowiecki J, Penka M, Widmann R et al (2007) Non-inferiority of anagrelide compared to hydroxyurea in newly diagnosed patients with essential thrombocythaemia: The ANAHYDRET study. In: 49th Annual Society of Hematology Annual Meeting, Atlanta, USA, 8-11 December
35. Najean Y, Rain JD, The French Polycythemia Study Group (1997) Treatment of polycythemia vera: Use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. Blood 89:2319-2327
36. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T (2000) Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: Long-term follow-up of a randomized clinical trial. Br J Haematol 110:577-583 doi: 10.1046/j.1365-2141.2000.02188.x
37. Sterkers Y, Preudhomme C, Lai JL, Demory JL, Caulier MT, Wattel E et al (1998) Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: High proportion of cases with 17p deletion. Blood 91:616-622
38. Randi ML, Fabris F, Girolami A (2002) Second malignancies in patients with essential thrombocythaemia. Br J Haematol 116:923-924 doi: 10.1111/ j.1365-2141.2002.3346_1.x
39. Murphy S, Peterson P, Iland H, Laszlo J (1997) Experience of the Polycythemia Vera Study Group with essential thrombocythemia: A final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin Hematol 34:29-39
40. Gwilt PR, Tracewell WG (1998) Pharmacokinetics and pharmacodynamics of hydroxyurea. Clin Pharmacokinet 34:347-358 doi: 10.2165/ 00003088-199834050-00002
41. Thiele J, Kvasnicka HM, Ollig S, Schmitt-Graff A (2005) Anagrelide does not exert a myelodysplastic effect on megakaryopoiesis: A comparative immunohistochemical and morphometric study with hydroxyurea. Histol Histopathol 20:1071-1076
42. Bernasconi P, Boni M, Cavigliano PM, Calatroni S, Brusamolino E, Passamonti F et al (2002) Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): Distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea. Leukemia 16:2078-2083 doi: 10.1038/sj.leu.2402638
43. Chim CS, Kwong YL, Lie AK, Ma SK, Chan CC, Wong LG et al (2005) Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia. Arch Intern Med 165:2651-2658 doi: 10.1001/archinte.165.22.2651
44. Fruchtman SM, Mack K, Kaplan ME, Peterson P, Berk PD, Wasserman LR (1997) From efficacy to safety: A Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol 34:17-23
45. Kiladjian JJ, Rain JD, Bernard JF, Briere J, Chomienne C, Fenaux P (2006) Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost 32:417-421 doi: 10.1055/s-2006-942762
46. Najean Y, Rain JD (1997) Treatment of polycythemia vera: The use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 90:3370-3377
47. Stevens MR (1999) Hydroxyurea: An overview. J Biol Regul Homeost Agents 13:172-175
48. Lossos IS, Matzner Y (1995) Hydroxyurea-induced fever: Case report and review of the literature. Ann Pharmacother 29:132-133
49. Braester A, Quitt M (2000) Hydroxyurea as a cause of drug fever. Acta Haematol 104:50-51 doi: 10.1159/000041071
50. Lannemyr O, Kutti J (1999) Hydroxyurea as a cause of drug fever in essential thrombocythaemia. Eur J Haematol 62:354-355
51. Kennedy BJ, Smith LR, Goltz RW (1975) Skin changes secondary to hydroxyurea therapy. Arch Dermatol 111:183-187 doi: 10.1001/ archderm.111.2.183
52. Dumont-Wallon G, Milpied-Homsi B, Morineau N (2006) Effets secondaires cutanéomuqueux de l'hydroxyurée: Étude prospective sur 27 patients. Hematologie 12:262-266
53. Zaccaria E, Cozzani E, Parodi A (2006) Secondary cutaneous effects of hydroxyurea: Possible pathogenetic mechanisms. J Dermatolog Treat 17:176-178 doi: 10.1080/09546630600780494
54. Best PJ, Petitt RM (1998) Multiple skin cancers associated with hydroxyurea therapy. Mayo Clin Proc 73:961-963
55. Ravandi-Kashani F, Cortes J, Cohen P, Talpaz M, O'Brien S, Markowitz A et al (1999) Cutaneous ulcers associated with hydroxyurea therapy in myeloproliferative disorders. Leuk Lymphoma 35:109-118 doi: 10.3109/ 10428199909145710
56. Gilbert HS (2003) Modern treatment strategies in polycythemia vera. Semin Hematol 40:26-29
57. Barbui T, Finazzi G (2005) When and how to treat essential thrombocythemia. N Engl J Med 353:85-86 doi: 10.1056/NEJMe058093
58. Dingli D, Tefferi A (2005) A critical review of anagrelide therapy in essential thrombocythemia and related disorders. Leuk Lymphoma 46:641-650 doi: 10.1080/10428190400029817
59. Barbui T, Barosi G, Grossi A, Gugliotta L, Liberato LN, Marchetti M et al (2004) Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 89:215-232
60. Randi ML, Ruzzon E, Tezza F, Luzzatto G, Fabris F (2005) Toxicity and side effects of hydroxyurea used for primary thrombocythemia. Platelets 16:181-184 doi: 10.1080/09537100400020179
61. Barosi G, Besses C, Birgegard G, Briere J, Cervantes F, Finazzi G et al (2007) A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: Results of a consensus process by an international working group. Leukemia 21:277-280 doi: 10.1038/ sj.leu.2404473
62. Hong Y, Wang G, Del Arroyo AG, Hernandez J, Skene C, Erusalimsky JD (2006) Comparison between anagrelide and hydroxycarbamide in their activities against haematopoietic progenitor cell growth and differentiation: Selectivity of anagrelide for the megakaryocytic lineage. Leukemia 20:1117-1122 doi: 10.1038/sj.leu.2404180
63. Birgegard G, Bjorkholm M, Kutti J, Larfars G, Lofvenberg E, Markevarn B et al (2004) Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders. Haematologica 89:520-527
64. Fruchtman SM, Petitt RM, Gilbert HS, Fiddler G, Lyne A (2005) Anagrelide: Analysis of long-term efficacy, safety and leukemogenic potential in myeloproliferative disorders. Leuk Res 29:481-491 doi: 10.1016/j.leukres.2004.10.002
65. Steurer M, Gastl G, Jedrzejczak WW, Pytlik R, Lin W, Schlogl E et al (2004) Anagrelide for thrombocytosis in myeloproliferative disorders: A prospective study to assess efficacy and adverse event profile. Cancer 101:2239-2246 doi: 10.1002/cncr.20646
66. Penninga E, Jensen BA, Hansen PB, Clausen NT, Mourits-Andersen T, Nielsen OJ et al (2004) Anagrelide treatment in 52 patients with chronic myeloproliferative diseases. Clin Lab Haematol 26:335-340 doi: 10.1111/ j.1365-2257.2004.00637.x
67. Storen EC, Tefferi A (2001) Long-term use of anagrelide in young patients with essential thrombocythemia. Blood 97:863-866 doi: 10.1182/ blood.V97.4.863
68. Laguna MS, Kornblihtt LI, Marta RF, Michiels JJ, Molinas FC (2000) Effectiveness of anagrelide in the treatment of symptomatic patients with essential thrombocythemia. Clin Appl Thromb Hemost 6:157-161 doi: 10.1177/107602960000600307
69. Mills AK, Taylor KM, Wright SJ, Bunce I, Eliadis P, Brigden MC et al (1999) Efficacy, safety and tolerability of anagrelide in the treatment of essential thrombocythaemia. Aust N Z J Med 29:29-35
70. Petrides PE, Beykirch MK, Trapp OM (1998) Anagrelide, a novel platelet lowering option in essential thrombocythaemia: Treatment experience in 48 patients in Germany. Eur J Haematol 61:71-76
71. Anagrelide Study Group (1992) Anagrelide, a therapy for thrombocythemic states: Experience in 577 patients. Am J Med 92:69-76 doi: 10.1016/ 0002-9343(92)90017-6
72. Petitt RM, Silverstein MN, Petrone ME (1997) Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders. Semin Hematol 34:51-54
73. Mazzucconi MG, De Sanctis V, Chistolini A, Dragoni F, Mandelli F (1992) Therapy with anagrelide in patients affected by essential thrombocythemia: Preliminary results. Haematologica 77:315-317
74. Petrides PE (2004) Anagrelide: A decade of clinical experience with its use for the treatment of primary thrombocythaemia. Expert Opin Pharmacother 5:1781-1798 doi: 10.1517/14656566.5.8.1781
75. Barbui T (2004) The leukemia controversy in myeloproliferative disorders: Is it a natural progression of disease, a secondary sequela of therapy, or a combination of both. Semin Hematol 41:15-17 doi: 10.1053/j.seminhematol.2004.02.006
76. Mazzucconi MG, Redi R, Bernasconi S, Bizzoni L, Dragoni F, Latagliata R et al (2004) A long-term study of young patients with essential thrombocythemia treated with anagrelide. Haematologica 89:1306-1313
77. Zomas A, Marinakis T, Grigoraki V, Gortzolidis G, Arseni P, Skandali A et al (2002) The use anagrelide for control of thrombocytosis in Greek patients with myeloproliferative disorders. Haem 5:320-325
78. Birgegard G (2006) Anagrelide treatment in myeloproliferative disorders. Semin Thromb Hemost 32:260-266 doi: 10.1055/s-2006-939437
79. Gilbert HS (2001) Diagnosis and treatment of thrombocythemia in myeloproliferative disorders. Oncology 15:989-996 Williston Park
80. Mazur G, Wrobel T, Podolak-Dawidziak M, Kuliszkiewicz-Janus M, Potoczek S, Nosol J et al (2004) Anagrelide in the treatment of thrombocythemia essential (ET). Pol Arch Med Wewn 112:1445-1450
81. Tefferi A, Silverstein MN (1998) Treatment of polycythaemia vera and essential thrombocythaemia. Baillieres Clin Haematol 11:769-785 doi: 10.1016/S0950-3536(98)80038-3
82. Wadenvik H, Kutti J, Ridell B, Revesz P, Jacobsson S, Magnusson B et al (1991) The effect of alpha-interferon on bone marrow megakaryocytes and platelet production rate in essential thrombocythemia. Blood 77:2103-2108
83. Kiladjian JJ, Cassinat B, Turlure P, Cambier N, Roussel M, Bellucci S et al (2006) High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood 108:2037-2040 doi: 10.1182/blood-2006-03-009860
84. Samuelsson J, Mutschler M, Birgegard G, Gram-Hansen P, Bjorkholm M, Pahl HL (2006) Limited effects on JAK2 mutational status after pegylated interferon alpha-2b therapy in polycythemia vera and essential thrombocythemia. Haematologica 91:1281-1282
85. Jones AV, Silver RT, Waghorn K, Curtis C, Kreil S, Zoi K et al (2006) Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood 107:3339-3341 doi: 10.1182/ blood-2005-09-3917
86. Seewann HL (1993) Interferon therapy in essential thrombocythemia. Wien Med Wochenschr 143:420-424
87. Yataganas X, Meletis J, Plata E, Viniou N, Deligiannis F, Tsekoura C et al (1991) alpha Interferon treatment of essential thrombocythaemia and other myeloproliferative disorders with excessive thrombocytosis. Eur J Cancer 27(Suppl 4):S69-S71
88. Samuelsson J, Hasselbalch H, Bruserud O, Temerinac S, Brandberg Y, Merup M et al (2006) A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: Feasibility, clinical and biologic effects, and impact on quality of life. Cancer 106:2397-2405 doi: 10.1002/cncr.21900
89. Lengfelder E, Griesshammer M, Hehlmann R (1996) Interferon-alpha in the treatment of essential thrombocythemia. Leuk Lymphoma 22(Suppl 1):135-142 doi: 10.3109/10428199609074371
90. Lengfelder E, Berger U, Hehlmann R (2000) Interferon alpha in the treatment of polycythemia vera. Ann Hematol 79:103-109 doi: 10.1007/ s002770050563
91. Gilbert HS (2002) Other secondary sequelae of treatments for myeloproliferative disorders. Semin Oncol 29:22-27
92. Gisslinger H, Chott A, Scheithauer W, Gilly B, Linkesch W, Ludwig H (1991) Interferon in essential thrombocythaemia. Br J Haematol 79(Suppl 1):42-47 doi: 10.1111/j.1365-2141.1991.tb08118.x
93. Çabuk M, Pirildar T, Ceylan C, Koral L, Kirmaz C, Kiliccioglu B et al (2003) Arthritis induced by interferon-alpha therapy in a patient with essential thrombocythemia. Leuk Lymphoma 44:377-378 doi: 10.1080/ 1042819021000029948
94. De Salvo L, Plumacher Z, Gomez O, Weir-Medina J, Paz L, Salas D (1996) Hypertriglyceridemia following treatment with interferon alpha in essential thrombocythemia. Invest Clin 37:177-181
95. Vardizer Y, Linhart Y, Loewenstein A, Garzozi H, Mazawi N, Kesler A (2003) Interferon-alpha-associated bilateral simultaneous ischemic optic neuropathy. J Neuroophthalmol 23:256-259 doi: 10.1097/ 00041327-200312000-00003
96. Merup M, Aberg W, Lofvenberg E, Svensson E, Engman K, Paul C et al (2002) Symptoms, symptom distress and health-related quality of life in patients with polycythaemia vera or essential thrombocythaemia during treatment with interferon-alpha. Acta Oncol 41:50-55 doi: 10.1080/ 028418602317314064
97. Malek-Ahmadi P, Hilsabeck RC (2007) Neuropsychiatric complications of interferons: Classification, neurochemical bases, and management. Ann Clin Psychiatry 19:113-123 doi: 10.1080/10401230701333038
98. Malek-Ahmadi P (2001) Mood disorders associated with interferon treatment: Theoretical and practical considerations. Ann Pharmacother 35:489-495 doi: 10.1345/aph.10172
99. Quintas-Cardama A, Kantarjian HM, Giles F, Verstovsek S (2006) Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders. Semin Thromb Hemost 32:409-416 doi: 10.1055/s-2006-942761
100. Alvarado Y, Cortes J, Verstovsek S, Thomas D, Faderl S, Estrov Z et al (2003) Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia. Cancer Chemother Pharmacol 51:81-86 doi: 10.1007/s00280-002-0533-4
101. Langer C, Lengfelder E, Thiele J, Kvasnicka HM, Pahl HL, Beneke H et al (2005) Pegylated interferon for the treatment of high risk essential thrombocythemia: Results of a phase II study. Haematologica 90:1333-1338
102. Jabbour E, Kantarjian H, Cortes J, Thomas D, Garcia-Manero G, Ferrajoli A et al (2007) PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: Final result of a Phase 2 study. Cancer 110:2012-2018 doi: 10.1002/cncr.23018
103. Griesshammer M (2006) Risk factors for thrombosis and bleeding and their influence on therapeutic decisions in patients with essential thrombocythemia. Semin Thromb Hemost 32:372-380 doi: 10.1055/ s-2006-942758
104. Wolanskyj AP, Lasho TL, Schwager SM, McClure RF, Wadleigh M, Lee SJ et al (2005) JAK2 mutation in essential thrombocythaemia: Clinical associations and long-term prognostic relevance. Br J Haematol 131:208-213 doi: 10.1111/j.1365-2141.2005.05764.x
105. Tefferi A (2006) Essential thrombocythemia: Scientific advances and current practice. Curr Opin Hematol 13:93-98
106. Kittur J, Knudson RA, Lasho TL, Finke CM, Gangat N, Wolanskyj AP et al (2007) Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer 109:2279-2284 doi: 10.1002/cncr.22663
107. Finazzi G, Rambaldi A, Guerini V, Carobbo A, Barbui T (2007) Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica 92:135-136 doi: 10.3324/haematol.10634
108. Hsiao HH, Yang MY, Liu YC, Lee CP, Yang WC, Liu TC et al (2007) The association of JAK2(V617F) mutation and leukocytosis with thrombotic events in essential thrombocythemia. Exp Hematol 35:1704-1707 doi: 10.1016/j.exphem.2007.08.011
109. Tefferi A, Elliott M (2007) Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost 33:313-320 doi: 10.1055/s-2007-976165
110. Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A (2006) Essential thrombocythemia beyond the first decade: Life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc 81:159-166
111. Griesshammer M, Struve S, Harrison CM (2006) Essential thrombocythemia/ polycythemia vera and pregnancy: The need for an observational study in Europe. Semin Thromb Hemost 32:422-429 doi: 10.1055/s-2006-942763
112. Kiladjian JJ, Casadevall N, Vainchenker W, Fenaux P (2007) The first international meeting on V617F JAK2 mutation and its relevance in Philadelphia-negative myeloproliferative disorders. Pathol Biol (Paris) 55:85-87 doi: 10.1016/j.patbio.2006.06.004